The present invention relates to a device for blinding the administration of nonsolid pharmaceutical presentations. The device is in particular an opaque container which has at least two attachments, one of which is intended for connection to a dispenser for the pharmaceutical presentation, and the other of which is intended for connection to an applicator, the inside of said container having means for holding back the pharmaceutical presentation.
|
2. An opaque container (1) for blinding the administration of nonsolid pharmaceutical presentations in clinical trials on mammals, which has at least two attachments (2,3), one of which is intended for connection to a dispenser for the pharmaceutical presentation, and the other of which is intended for connection to an applicator, the attachments in the inside of the container having a continuous connection (5) ensuring that the pharmaceutical presentation is transported through the container (1).
1. An opaque container (1) for blinding the administration of nonsolid pharmaceutical presentations in clinical trials on mammals, which has at least two attachments, (2, 3), one of which is intended for connection to a dispenser for the pharmaceutical presentation, and the other of which is intended for connection to an applicator, the inside of said container (1) having means (4) for holding back the pharmaceutical presentation, wherein the attachment intended for connection to the applicator has a closure inside the container.
3. An opaque container (1) for blinding the administration of nonsolid pharmaceutical presentations in clinical trials on mammals, which has at least three attachments (2,2,3), two of which are intended for connection to a dispenser for the pharmaceutical presentation, and the third one of which is intended for connection to an applicator, the inside of said container (1) having means (4) for holding back the pharmaceutical presentation, and one of the attachments (2) which are intended for connection to a dispenser has a continuous connection (5) to the attachment (3) which is intended for connection to the applicator, and the connection ensures that the pharmaceutical presentation is transported through the container (1).
4. A device for blinding the administration of nonsolid pharmaceutical presentations in clinical trials on mammals, comprising a container (1) as claimed in
5. The device as claimed in
6. The container (1) as claimed in
7. The container (1) as claimed in
8. The container (1) as claimed in
9. The container as claimed in
10. The container as claimed in
11. A device for blinding the administration of nonsolid pharmaceutical presentations in clinical trials on mammals, comprising a container (1) as claimed in
12. A device for blinding the administration of nonsolid pharmaceutical presentations in clinical trials on mammals, comprising a container (1) as claimed in
13. The device as claimed in
14. The device as claimed in
15. The container (1) as claimed in
16. The container (1) as claimed in
17. The container (1) as claimed in
18. The container (1) as claimed in
19. The container (1) as claimed in
20. The container (1) as claimed in
|
The invention relates to a device for blinding the administration of nonsolid pharmaceutical presentations in clinical trials on mammals.
In the prior art there are various known ways of blinding the administration of nonsolid presentations in clinical trials. If the pharmaceutical presentation is a colorless liquid, then the pharmaceutical presentation can be replaced for example by a physiological saline solution. In the case of colored presentations, an opaque application system, for example, can be used for administration. It is obvious that these methods are not suitable for intrapulmonary administration. In the case of clinical testing of nonsolid presentations which are administered by the intrapulmonary route, the double-blind technique is therefore used. [J. A. Schwarz (1995), Leitfaden Klinische Prüfungen: Planung, Organisation, Durchführung, Dokumentation und Überwachung (Guidelines for Clinical Trials: Planning, Organization, Conduct, Documentation and Monitoring), ECV-Editio Cantor-Verlag; Der pharmazeutische Betrieb; Vol. 43; or M. S. Kwong et al., Double-Blind Clinical Trial of Calf Lung Surfactant Extract for the Prevention of Hyaline Membrane Disease in Extremely Premature Infants; Pediatrics (1985), Vol. 76, No. 4, pages 585-592]. Here, the test substance is administered by persons who are not otherwise involved with the patient during the clinical study. These persons are then under a pledge of secrecy. The double-blind technique can only be carried out with considerable outlay in terms of personnel and costs.
It is an object of the present invention to make available a device for blinding the administration of nonsolid pharmaceutical presentations in clinical trials in a simple manner and without using the double-blind technique.
The subject of the invention is therefore a device for blinding the administration of nonsolid pharmaceutical presentations in clinical trials on mammals.
In one aspect of the invention, the device is an opaque container which has at least two attachments, one of which is intended for connection to.a dispenser for the pharmaceutical presentation, and the other of which is intended for connection to an applicator, and where the inside of the container has means for holding back the pharmaceutical presentation (hereinafter also referred to as the nonflow-type configuration).
When such a container is connected to a dispenser and to an opaque applicator for administration of a pharmaceutical presentation, said pharmaceutical presentation is held back in the container upon application, but this cannot be detected by the person charged with the administration.
In a further aspect, the invention concerns an opaque container which has at least two attachments, one of which is intended for connection to a dispenser for the pharmaceutical presentation, and the other of which is intended for connection to an applicator, and where the attachments in the inside of the container have a continuous connection which ensures that the pharmaceutical presentation is transported through the container (hereinafter also referred to as the flow-type configuration).
If this container is used together with a dispenser and an opaque applicator to administer the pharmaceutical presentation, said pharmaceutical presentation is transported through the container and administered to the patient, but this cannot be detected by the person charged with the administration.
In a further aspect, the invention relates to a container with which it is possible both to transport the pharmaceutical presentation through the container and also to hold back the pharmaceutical presentation in the same container. A further subject of the invention is therefore an opaque container which has at least three attachments, two of which are intended for connection to a dispenser for the pharmaceutical presentation, and the third one of which is intended for connection to an applicator, and where the inside of the container has means for holding back the pharmaceutical presentation, and one of the attachments which are intended for connection to a dispenser has a continuous connection to the attachment which is intended for connection to the applicator, and the connection ensures that the pharmaceutical presentation is transported through the container.
Depending on the choice of attachments for connection to the dispenser and the applicator, the pharmaceutical presentation is either transported through the container and administered to the patient or is held back in the container.
The container according to the invention can be rigid or flexible and can be made from all suitable solid materials. The container is advantageously one which has been made using plastic or rubber (e.g. film bag made of PVC film).
The means for holding back the pharmaceutical presentation inside the container is preferably an absorbent material which is not able to completely take up the nonsolid pharmaceutical presentation (e.g. absorbent fabric). However, the container can also be completely or partially hollow on its inside. The pharmaceutical presentation can also be held back in this way. Depending on the nature of the means for holding back the pharmaceutical presentation (hereinafter also referred to as the test substance), the container is preferably dimensioned such that it can completely accommodate the test substance to be administered. In a preferred embodiment of the invention, the container is dimensioned such that it can accommodate 300 ml of liquid. Containers are preferred which have an internal volume of 500 ml to 3000 ml, and particularly preferred are those which have an internal volume of 1000 ml to 2000 ml.
Depending on the weight and the quantity of the test substance to be administered, the container should preferably have a correspondingly greater own weight. This makes it difficult or even impossible for the person administering the substance to compare the weight of the container before and after administration of the test substance. Containers with an own weight of more than 1 kg have generally proven advantageous in this respect. In a preferred embodiment of the invention, the inside of the container can have weight elements in order to ensure an adequate own weight of the container. The weight elements can for example be hard rubber disks.
The attachments which the container according to the invention possesses are preferably commercially available Luer lock attachments which are suitable for connection to the dispenser and applicator. The attachments preferably have different markings for purposes of differentiation. The dispenser is preferably a commercially available syringe which can be connected to the attachment on the container directly or via a tube connection. The applicator is preferably an opaque applicator, for example an opaque catheter system, preferably a catheter system which is suitable for intrapulmonary administration of a nonsolid pharmaceutical presentation. Such catheters are known to those versed in the art.
The container according to the invention which holds back the pharmaceutical presentation can, at the attachment intended for connection to the dispenser, also be connected to a tube which leads into the inside of the container and has an open end through which the pharmaceutical presentation is dispensed into the inside of the container. The tube advantageously has a plurality of openings in the tube line. This ensures rapid dispensing of the pharmaceutical presentation into the inside of the container. The tube can also advantageously have a nonreturn valve which ensures that the pharmaceutical presentation dispensed into the inside of the container cannot return into the tube. The attachment intended for connection to the applicator can have a closure inside the container, so that the pharmaceutical presentation held back cannot escape into the applicator. If so desired, this can entail a closed tube guided through the inside of the container. In a preferred embodiment of the invention, the two tubes leading into the inside of the container can be connected to one another via a Y-connector. The tube which leads to the attachment for the applicator is tied off sealingly or is tightly sealed by means of pinching or welding. The 3rd attachment of the Y-connector has an open cap through which the delivered pharmaceutical presentation can flow into the blinding bag.
The container according to the invention which ensures transport of the pharmaceutical presentation through the container advantageously has, inside the container, a continuous tube connection between the attachments. The container can be hollow or, if so desired, can also be filled with suitable materials, for example absorbent materials, and weight elements. The container is preferably designed corresponding to the container which holds back the pharmaceutical presentation in the container.
The container according to the invention can also have a venting device (e.g. valve) in order to compensate for pressure differences which arise thorugh the pharmaceutical preparation being held back in the container.
The containers according to the invention are suitable, together with a dispenser and an applicator, for advantageously blinding the administration of nonsolid presentations, in particular liquid presentations, by the intrapulmonary route. Examples of liquid presentations are pharmaceutical presentations which have the properties of natural lung surfactant. Reference is made by way of example to the presentations described in WO95/32992.
If, during a clinical trial, containers with and containers without retention of the pharmaceutcial presentation are used by the same person, the various containers are preferably designed in such a way that a distinction cannot be made between them by said person.
Illustrative embodiments of the invention are explained in more detail below with reference to the drawings, in which:
A blinding bag 10 according to the invention, represented by way of example in
A blinding bag 40 according to the invention, shown according to
Patent | Priority | Assignee | Title |
9861312, | Jan 16 2012 | Sanofi-Aventis Deutschland GmbH | Blinding kit for clinical trials |
9867567, | Jan 16 2012 | Sanofi-Aventis Deutschland GmbH | Blinding kit for clinical trials |
Patent | Priority | Assignee | Title |
3572340, | |||
3958080, | Jun 11 1974 | Josef Kaiser AG Fahrzeugwerk | Visual inspection apparatus for conduits |
4767415, | Mar 02 1984 | Institute for Industrial Research and Standards | Syringe and non-linear passageway reservoir for use therewith |
5376081, | Mar 25 1991 | Opaque syringe | |
5457492, | Jul 15 1993 | Citizen Watch Co., Ltd. | Light source device for an image processor |
5658248, | Aug 04 1995 | LocalMed, Inc. | Double-blind infusion device and method |
5858015, | Sep 29 1993 | Dideco S.P.A. | Container for blood |
5980834, | Jul 25 1996 | The United States of America as represented by the Secretary of Commerce | Sample storage devices |
6287284, | Sep 27 1999 | Saint-Gobain Performance Plastics Corporation | Silicone bag assembly |
20020094506, | |||
DE255260, | |||
WO9705914, |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Apr 20 2001 | SCHAFFER, PETER | BYK Gulden Lomberg Chemische Fabrik GmbH | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 011813 | /0191 | |
Apr 26 2001 | Altana Pharma AG | (assignment on the face of the patent) | / | |||
Jul 01 2002 | BYK Gulden Lomberg Chemische Fabrik GmbH | Altana Pharma AG | CHANGE OF NAME SEE DOCUMENT FOR DETAILS | 013751 | /0522 | |
Jun 14 2007 | Altana Pharma AG | Nycomed GmbH | CHANGE OF NAME SEE DOCUMENT FOR DETAILS | 019781 | /0225 |
Date | Maintenance Fee Events |
Aug 11 2004 | ASPN: Payor Number Assigned. |
Sep 15 2006 | M1551: Payment of Maintenance Fee, 4th Year, Large Entity. |
Sep 09 2010 | M1552: Payment of Maintenance Fee, 8th Year, Large Entity. |
Nov 14 2014 | REM: Maintenance Fee Reminder Mailed. |
Apr 08 2015 | EXP: Patent Expired for Failure to Pay Maintenance Fees. |
Date | Maintenance Schedule |
Apr 08 2006 | 4 years fee payment window open |
Oct 08 2006 | 6 months grace period start (w surcharge) |
Apr 08 2007 | patent expiry (for year 4) |
Apr 08 2009 | 2 years to revive unintentionally abandoned end. (for year 4) |
Apr 08 2010 | 8 years fee payment window open |
Oct 08 2010 | 6 months grace period start (w surcharge) |
Apr 08 2011 | patent expiry (for year 8) |
Apr 08 2013 | 2 years to revive unintentionally abandoned end. (for year 8) |
Apr 08 2014 | 12 years fee payment window open |
Oct 08 2014 | 6 months grace period start (w surcharge) |
Apr 08 2015 | patent expiry (for year 12) |
Apr 08 2017 | 2 years to revive unintentionally abandoned end. (for year 12) |